Health Care/Hospital

United Imaging Healthcare Releases 2024 ESG Report, Driving Sustainable Development Through Innovation

SHANGHAI, April 29, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271) has released its 2024 Environmental, Social, and Governance (ESG) Report, reaffirming its mission to bring Equal Healthcare for All. The report outlines continued progress in sustainability, compliance, and corporate...

2025-04-29 14:50 1906

Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025

SHANGHAI, April 28, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancer, today announced it will present preclinical data on a ...

2025-04-29 08:08 1704

Complete Genomics, Velsera partner to integrate sequencing and analysis platforms

CHICAGO, April 28, 2025 /PRNewswire/ -- Complete Genomics,  a leading innovator in genomic sequencing announced a collaboration withVelsera , a leading global healthcare technology company, to deliver an end-to-end genetic testing solution...

2025-04-28 21:00 2163

Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE

HEFEI, China, April 28, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved Phase IIb clinical trial of KPG-818 capsule for the treatment of moderate to severe cutaneo...

2025-04-28 20:00 1637

Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)

* Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) * Findings reinforce clinical decision-making in long-term management of moderate-to-severe Crohn's disease and ulcerative colitis and underscore Celltrion's commitmen...

2025-04-28 20:00 2473

Sky Labs' CART BP pro at the Heart of New Research on Sleep Apnea and Nocturnal Hypertension

SEOUL, South Korea, April 28, 2025 /PRNewswire/ -- Sky Labs, a health-tech startup based in South Korea and the developer of CART BP pro—a ring-type, cuffless device for 24-hour blood pressure monitoring—announced that a research presentation by ProfessorJin Oh Na introduced the application of CA...

2025-04-28 20:00 1672

Health In Tech's CEO Tim Johnson Discusses Company in 2025, Revenue Growth, and Healthcare on "The Street Reports Podcast" Listen Now!

STUART, Fla., April 28, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is proud to share that CEOTim Johnson was featured on The Street Reports Podcast. Listen now:  https://thestreetreports.com/health-in-technologys-nasdaq-...

2025-04-28 19:00 2183

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY

* Total Revenue Reached RMB9.65 Billion, Up 21.0% Year-over-Year; among which Revenue from Continuing Operations ReachedRMB9.39 Billion, Up 23.1% Year-over-Year * Net Profit Attributable to the Owners of the Company Reached RMB3.67 Billion [1], Up 89.1% Year-over-Year; Diluted Earnings per Sha...

2025-04-28 17:33 2898

YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia

SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an investigator-initiated trial (IIT) of YOLT-101 (NCT064...

2025-04-28 13:22 2168

2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1

SHANGHAI, April 27, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared ...

2025-04-28 10:00 2151

ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting

SUZHOU, China, April 27, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster presentation at American Association for Cancer Resea...

2025-04-28 09:00 2187

Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025

CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced that its partner, Pfizer, has presented preclinical data on PF-08052666 (HBM9033; SGN-MesoC2), a first-in-class topoisome...

2025-04-28 08:00 1964

ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups

Ono Partnering with LabCentral and MBC BioLabs for Fifth Consecutive Year CAMBRIDGE, Mass., April 26, 2025 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral inCambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Tick...

2025-04-27 00:00 2546

Concord Medical Files Annual Report on Form 20-F for Fiscal 2024

BEIJING, April 25, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it filed its annual report on Form 20-F for t...

2025-04-26 06:00 4339

Zepp Health Corporation Files 2024 Annual Report on Form 20-F

MILPITAS, Calif., April 25, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has filed its annual report on Form 20-F for the full year endedDecember 31, 2024 with the U.S....

2025-04-26 05:00 4507

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

HONG KONG, April 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical Products Administration (NMPA) for its supplementary New D...

2025-04-26 01:24 3071

Baijiayun Announces Plan to Invest Tens of Millions of Dollars Over Five Years to Build New Ecosystem for Autism Rehabilitation

BEIJING, April 25, 2025 /PRNewswire/ -- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ: RTC), a one-stop AI video solution provider, announced a Letter to Investors, in which Baijiayun CEO Mr.Yi Ma stated that following its partnership with Xinlantian, the company plans to invest tens...

2025-04-25 21:10 3920

WATERDROP FILES ANNUAL REPORT ON FORM 20-F FOR FISCAL YEAR 2024

BEIJING, April 25, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ende...

2025-04-25 18:52 3341

Meihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year Results

YANGZHOU, China, April 25, 2025 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced its financial...

2025-04-25 18:05 3108

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) ...

2025-04-25 17:44 2082
1 ... 43444546474849 ... 308

Week's Top Stories